OOIR: Observatory of International Research

Papers

(The median citation count of Trends in Cancer is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Subscription & copyright page	274
FBXW10: a male-biased E3 ligase in liver cancer	264
Engineering growth factor ligands and receptors for therapeutic innovation	250
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	242
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	216
Revumenib: a new era in acute leukemia treatment	211
Advancements in organoid models emulating metastatic niches	210
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	201
Spliced to kill: RNA mis-splicing derived cancer neoantigens	199
Platelets: tailoring metastasis treatment	189
Tumor-resident microbes: the new kids on the microenvironment block	185
Navigating life as an early career researcher	177
Subscription & copyright page	167
Subscription and copyright page	165
Advisory Board and Contents	159
Leveraging circulating microbial DNA for early cancer detection	157
Onco-condensates: formation, multi-component organization, and biological functions	152
Accessing the vasculature in cancer: revising an old hallmark	144
Engine shutdown: migrastatic strategies and prevention of metastases	143
Subscription & copyright page	131
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	115
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	115
From prediction to precision: how immunopeptidomics advances neoantigen discovery	108
Gut microbiota – a double-edged sword in cancer immunotherapy	107
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	105

The evolving landscape of brain metastasis: volume II	103
Oncogenic competence: balancing mutations, cellular state, and microenvironment	102
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	101
Diet, nutrient supply, and tumor immune responses	99
Chromatin as an old and new anticancer target	94
Regulation of metastatic organotropism	92
Recent developments in myeloid immune modulation in cancer therapy	86
GOT2 consider the tumor microenvironment	83
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	80
FGFR rearrangements: oncogenic drivers and therapeutic targets	79
Benefits and opportunities of the transgenic Oncopig cancer model	77
Crosstalk of T cells within the ovarian cancer microenvironment	76
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	74
Circulating tumor DNA in biliary tract cancers: challenges, opportunities, and clinical readiness	73
Cell death, therapeutics, and the immune response in cancer	71
Neural hijacking in cancer metabolism: from nutrients to organelles	70
Advisory Board and Contents	69
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	66
Subscription & copyright page	66
Palmitate paves the way to lung metastasis	65
Insights on ErbB glycosylation – contributions to precision oncology	65
Scaling data toward pan-cancer foundation models	63
Genetic immune escape in cancer: timing and implications for treatment	63
Toward mutational epidemiology: using mutational signatures of environmental exposures to assess cancer risk	61
Organellar pH as an emerging vulnerability to exploit in cancer	61
Planning for cancer: building accessible and high-quality survivorship care for all	61
The emerging field of oncolytic virus-based cancer immunotherapy	61
Inflammation: the incubator of the tumor microenvironment	60
Clinical and translational relevance of intratumor heterogeneity	59
Subscription & copyright page	57
Advisory Board and Contents	56
Advisory Board and Contents	56
Advisory Board and Contents	56
Advisory Board and Contents	55
Advancing cancer precision surgery with the tumor coagulome	55
Emerging mechanisms of telomerase reactivation in cancer	54
Prospects for understanding and exploiting the consequences of hyperactivation lethality	53
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	51
Circulating cell-free DNA-based multi-cancer early detection	50
Microbiome: a driver of pancreatic inflammation and tumorigenesis	50
B7-H3: a robust target for immunotherapy in prostate cancer	49
RHOA takes the RHOad less traveled to cancer	49
Cuproptosis in cancer: from molecular mechanisms to therapeutic intervention	49
Updating cancer research with patient-focused networks	49
Molecular and clinical insights into early-onset endometrial cancer	48
Gut microbial metabolites for potentiating cancer therapy	48
Stress granules and hormetic adaptation of cancer	47
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	47
Advisory Board and Contents	47
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	47

Advisory Board and Contents	46
A macrophage-neutrophil program drives mammary carcinogenesis	46
Advisory Board and Contents	45
Subscription & copyright page	45
Time-of-day dependency of adoptive cell therapies	43
Neoantigen-directed therapeutics in the clinic: where are we?	43
Beyond safety: suicide systems in cell-based cancer therapies	43
Mechanistic cancer prevention comes of age	43
Subscription & copyright page	43
Orchestrating tumor-immune epigenetics via SERT–H3Q5ser axis	43
The promise of TIL therapy for glioblastoma	43
Targeting TIM-3 to halt lung precancer progression	43
Advisory Board and Contents	43
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	42
Branched chain amino acids and their aberrant metabolism in cancer	40
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	40
RNA vaccines for cancer: revolutionizing immunization strategies	39
Leveraging space innovations for cancer breakthroughs on Earth	39
Functional heterogeneity of fibroblasts in primary tumors and metastases	37
CAR T cell persistence in cancer	37
Ferroptosis vulnerability in FLT3-mutant leukemia	35
Advisory Board and Contents	35
Subscription & copyright page	35
Engineered bacterial therapeutics for detecting and treating CRC	34
ApCAFs: spatial niches and therapeutic insights across cancers	34
Advisory Board and Contents	34
Space in cancer biology: its role and implications	34
Dying to survive: harnessing inflammatory cell death for better immunotherapy	33
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	33
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	33
Advisory Board and Contents	32
Advisory Board and Contents	32
Neural circuits in lung adenocarcinoma modulate immunosurveillance	32
Clonal evolution and hierarchy in myeloid malignancies	31
Subscription & copyright page	31
Advisory Board and Contents	31
Dissecting histological transformation	31
Subscription & copyright page	30
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	30
Genitourinary cancer neoadjuvant therapies: current and future approaches	30
Addressing the genetic/nongenetic duality in cancer with systems biology	30
Mesothelioma: a systemic therapy clinical trials snapshot	29
Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics	29
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	28
The development of therapy related myeloid neoplasms in childhood cancer survivors	28
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	28
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	27
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	27
Immunomodulation by endothelial cells: prospects for cancer therapy	26
NETscape or NEThance: tailoring anti-cancer therapy	26
Next-generation cancer vaccines and emerging immunotherapy combinations	26
Lifileucel: the first cellular therapy approved for solid tumours	26
Successfully targeting the cancer system with metronomics for medulloblastoma	25
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	25
Subscription & copyright page	25
How DNA methylation predicts response to cancer therapies	24
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome	24
Future perspectives on engineered T cells for cancer	23
The extracellular matrix in cancer: from understanding to targeting	23
Embracing diversity: macrophage complexity in cancer	23
Persisting cancer cells are different from bacterial persisters	23
Tissue architecture in tumor initiation and progression	22
Think zebras: challenges and opportunities for treating rare cancers	22
Deciphering the roles of ABCB5 in normal and cancer cells	22
How cancer cells make and respond to interferon-I	22
Subscription & copyright page	22
Fueling the revolution: RIBOTACs manipulating RNA decay	21
Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer	21
Towards enhancing the predictive value of the microbiota for cancer immunotherapy	21
Emerging and extensive clonal evolution in the pancreas	21
Extracellular vesicle lipids in cancer immunoevasion	21
The clinical landscape of CAR-engineered unconventional T cells	20
TET2, tumor control, and CAR T cell hyperproliferation	20
Enhancing dendritic cells by inhibiting BCL2	20
Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations	20
Subscription & copyright page	20
Poised epigenetic states dictate metastatic fitness	20
Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance	20
Circulating extracellular vesicles and tumor cells: sticky partners in metastasis	19
Navigating the biophysical landscape: how physical cues steer the journey of bone metastatic tumor cells	19

Hypoxia orchestrates the lymphovascular–immune ensemble in cancer	19
Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity	19
Intracranial CAR-T cell delivery in glioblastoma patients	19
Defining obesity in the context of cancer: thinking beyond body mass index	19
Acetylation: a new target for protein degradation in cancer	19
Tackling the next decade of cancer research	19
Interferon epsilon and ovarian cancer	18
Watching cancer begin: emerging tools to visualize the first steps of tumorigenesis	18
Tissue mechanics in tumor heterogeneity and aggression	18
ALPK1 agonists ignite innate immunity in anticancer therapy	18
Time to heal: inhibiting fibrosis prevents glioblastoma recurrence	18
A growing entourage for heterotypic circulating tumor cell clusters	17
Subscription & copyright page	17
Intratumoral immune cell manipulations as a strategy to enhance cancer vaccine efficiency	17
The redox paradox in HGGs: ROS as drivers and destroyers	17
Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy	17
Dynamic immune signatures as biomarkers for irAEs	17
Limited dsRNA editing impedes leukemia stem cells	17
Mechanisms of T cell exhaustion guiding next-generation immunotherapy	17
Current landscape of CD3 bispecific antibodies in hematologic malignancies	17
The tumor-draining lymph node as a reservoir for systemic immune surveillance	17
Advisory Board and Contents	16
Harnessing FLASH irradiation to improve immunotherapy of medulloblastoma	16
mtDNA transfer from senescent cancer cells to MDSCs promotes immunosuppression	16
Adaptive inhibition of CGAS signaling by TREX1	16
Wargaming cancer: a strategy for future precision oncology?	16
Targeting phagocytosis to enhance antitumor immunity	16
Ancestry-defined molecular taxonomy of prostate cancer	15
Reductive stress in cancer: coming out of the shadows	15
Lifestyle and host determinants of antitumor immunity and cancer health disparities	15
Spatial promoter–enhancer hubs in cancer: organization, regulation, and function	15
Spatially resolving cancer: from cell states to therapy	15
Subscription & copyright page	15
KRAS inhibitors: resistance drivers and combinatorial strategies	15
A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy	15
Polo-like kinases as immune modulators: a new frontier in cancer immunotherapy	14
Many faces, many places: delving deeper into CAF heterogeneity in NSCLC	14
Myeloid cell path to malignancy: insights into liver cancer	14
Advances in targeting RNA modifications for anticancer therapy	14
State-matched organoid models to fight pancreatic cancer	14
Lost but not least: Y chromosome loss as a driver of cancer	13
Subscription & copyright page	13
Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma	13
Advisory Board and Contents	13
Label-free optical imaging for brain cancer assessment	13
The peritumor microenvironment: physics and immunity	13
Subscription & copyright page	13
Disarming cancer resistance: FAK as a therapeutic target	13
Advisory Board and Contents	13
Impact of tissue-agnostic approvals on management of primary brain tumors	13
Into the era of mycobiome-driven cancer research	13
Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies	13
Emerging roles of nucleotide metabolism in cancer	13
Neuro-immune interactions and immuno-oncology	13
Immune organoids: from tumor modeling to precision oncology	12
The future of cancer research: invest now	12
Immunometabolism of CD8+ T cell differentiation in cancer	12
Metabolic landscape of disseminated cancer dormancy	12
Drug independence and the curability of cancer by combination chemotherapy	12
The emerging roles of the urea cycle in tumor microenvironment and therapies	12
Epigenetic control of immunoevasion in cancer stem cells	12
Advisory Board and Contents	12
Host and microbiome lipid metabolism in colorectal cancer development and therapy	12
CX3CL1: a key switch of cell death immunogenicity	11
Immune cells in residual disease and recurrence	11
Advisory Board and Contents	11
Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?	11
Cancer fitness genes: emerging therapeutic targets for metastasis	11
Subscription and copyright page	11
γδT cells and breast cancer: wicked allies	11
Targeting vulnerabilities of aneuploid cells for cancer therapy	10
Optimizing the future: how mathematical models inform treatment schedules for cancer	10
Trends in cancer imaging	10
Neuronal and tumourigenic boundaries of glioblastoma plasticity	10
Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy	10
Targeting cancer stem cells in multiple myeloma	10
Plastic persisters: revival stem cells in colorectal cancer	10
Generation of tumor neoantigens by RNA splicing perturbation	10
Advisory Board and Contents	9
EZHIP’s role in diffuse midline glioma: echoes of oncohistones?	9
A lysosomal requiem for glioblastoma cells	9
Immune mechanisms of toxicity from checkpoint inhibitors	9
Anxiolytics cause anxiety in pancreatic cancer	9
CD4+ T cells in antitumor immunity	9
Therapeutic targeting of regulatory T cells in cancer	9
The urgent need to improve childhood cancer cachexia	8
Beyond probiotics: postbiotics sensitize cancer cells to immune checkpoint inhibitors	8
HSPC-like blasts in acute lymphoblastic leukemia: biology and therapeutic opportunities	8
Immune vulnerabilities of mutant KRAS in pancreatic cancer	8
A new BRAF inhibitor breaks resistance barriers	8
Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity	8
Targeting phagocytosis to enhance antitumor immunity	8
Subscription &copyright page	8
Viral mimicry in cancer therapy	8
Subscription & copyright page	8